AXSM Axsome Therapeutics Inc

Price (delayed)

$72.99

Market cap

$2.73B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.7

Enterprise value

$2.57B

Sector: Healthcare
Industry: Biotechnology

Highlights

The quick ratio has grown by 20% from the previous quarter
Axsome Therapeutics's debt has surged by 143% YoY and by 137% QoQ
The net income has plunged by 85% YoY and by 4% from the previous quarter

Key stats

What are the main financial stats of AXSM
Market
Shares outstanding
37.34M
Market cap
$2.73B
Enterprise value
$2.57B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
20.12
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$97.07M
EBITDA
-$97.05M
Free cash flow
-$75.5M
Per share
EPS
-$2.7
Free cash flow per share
-$2.02
Book value per share
$3.63
Revenue per share
$0
TBVPS
$5.46
Balance sheet
Total assets
$203.63M
Total liabilities
$68.37M
Debt
$48.03M
Equity
$135.26M
Working capital
$182.93M
Liquidity
Debt to equity
0.36
Current ratio
9.99
Quick ratio
9.95
Net debt/EBITDA
1.59
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-48.5%
Return on equity
-63.1%
Return on invested capital
-2,274.1%
Return on capital employed
-53%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AXSM stock price

How has the Axsome Therapeutics stock price performed over time
Intraday
0%
1 week
-3.86%
1 month
-14.04%
1 year
-16.07%
YTD
-10.41%
QTD
-10.41%

Financial performance

How have Axsome Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$95.83M
Net income
-$98.54M
Gross margin
N/A
Net margin
N/A
The net income has plunged by 85% YoY and by 4% from the previous quarter
The company's operating income has shrunk by 83% YoY and by 2.3% QoQ

Growth

What is Axsome Therapeutics's growth rate over time

Valuation

What is Axsome Therapeutics stock price valuation
P/E
N/A
P/B
20.12
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 68% YoY
The P/B is 25% lower than the 5-year quarterly average of 26.8 but 10% higher than the last 4 quarters average of 18.3
The equity has declined by 12% since the previous quarter

Efficiency

How efficient is Axsome Therapeutics business performance
The company's return on invested capital has shrunk by 118% YoY
The ROE has soared by 85% YoY and by 17% from the previous quarter
AXSM's ROA has soared by 64% YoY and by 16% QoQ

Dividends

What is AXSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXSM.

Financial health

How did Axsome Therapeutics financials performed over time
Axsome Therapeutics's total assets is 198% more than its total liabilities
AXSM's total liabilities has soared by 86% since the previous quarter and by 82% year-on-year
Axsome Therapeutics's debt is 64% lower than its equity
The debt to equity has soared by 177% QoQ but it has shrunk by 88% YoY
Axsome Therapeutics's debt has surged by 143% YoY and by 137% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.